First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

E. G.M. Couturier; R. Hering; C. A. Foster; T. J. Steiner; F. Clifford Rose

doi:10.1111/j.1526-4610.1991.hed3105296.x

First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

E. G.M. Couturier^*, R. Hering, C. A. Foster, T. J. Steiner, F. Clifford Rose

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

SYNOPSISGranisetron (BRL 43694), a selective 5‐HT₃ receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

Original language	English
Pages (from-to)	296-297
Number of pages	2
Journal	Headache: The Journal of Head and Face Pain
Volume	31
Issue number	5
DOIs	https://doi.org/10.1111/j.1526-4610.1991.hed3105296.x
Publication status	Published - 1 Jan 1991
Externally published	Yes

Access to Document

10.1111/j.1526-4610.1991.hed3105296.x

Link to publication in Scopus

Cite this

Couturier, E. G. M., Hering, R., Foster, C. A., Steiner, T. J., & Rose, F. C. (1991). First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache. Headache: The Journal of Head and Face Pain, 31(5), 296-297. https://doi.org/10.1111/j.1526-4610.1991.hed3105296.x

@article{2879f499304a4b93a9d86bbc31f5f361,

title = "First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache",

abstract = "SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.",

keywords = "5‐HT, acute migraine, granisetron, serotonin",

author = "Couturier, {E. G.M.} and R. Hering and Foster, {C. A.} and Steiner, {T. J.} and Rose, {F. Clifford}",

year = "1991",

month = "1",

day = "1",

doi = "10.1111/j.1526-4610.1991.hed3105296.x",

language = "English",

volume = "31",

pages = "296--297",

journal = "Headache",

issn = "0017-8748",

publisher = "Wiley-Blackwell",

number = "5",

}

First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache. / Couturier, E. G.M.; Hering, R.; Foster, C. A.; Steiner, T. J.; Rose, F. Clifford.

In: Headache: The Journal of Head and Face Pain, Vol. 31, No. 5, 01.01.1991, p. 296-297.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

AU - Couturier, E. G.M.

AU - Hering, R.

AU - Foster, C. A.

AU - Steiner, T. J.

AU - Rose, F. Clifford

PY - 1991/1/1

Y1 - 1991/1/1

N2 - SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

AB - SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

KW - 5‐HT

KW - acute migraine

KW - granisetron

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=0025739778&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.1991.hed3105296.x

DO - 10.1111/j.1526-4610.1991.hed3105296.x

M3 - Article

C2 - 1650335

AN - SCOPUS:0025739778

VL - 31

SP - 296

EP - 297

JO - Headache

JF - Headache

SN - 0017-8748

IS - 5

ER -